title: Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
abstract: Notch1 is a multifunctional transmembrane receptor that regulates cellular differentiation, development, proliferation, and survival in a variety of contexts. We have previously shown that Notch1 may function as a tumor suppressor and that histone deacetylase (HDAC) inhibitors can induce Notch1 expression in some endocrine cancers. Here, we showed that although there was minimal Notch1 expression in follicular thyroid cancer FTC236 and papillary thyroid cancer DRO cells, transfection of constitutive Notch1 plasmid into these cells led to growth inhibition, down-regulation of cyclin D1, and up-regulation of p21. Treatment of FTC236 cells with HDAC inhibitors valproic acid (1-4 mmol/L) or suberoyl bishydroxamic acid (10-30 micromol/L) induced functional Notch1 protein expression and suppressed cell growth in a dose-dependent manner. Notch1 siRNA interference blocked the antiproliferative effect of HDAC inhibitors. Western blot analysis revealed the reduction of cyclin D1 and the increase of p21 in HDAC inhibitor-treated cells. These results indicate that HDAC inhibitors activate Notch1 signaling in thyroid cancer cells and lead to the suppression of proliferation by cell cycle arrest. Our findings provide the first documentation of the role of Notch1 signaling as a tumor suppressor in DRO and FTC236 cells, suggesting that Notch1 activation may be a potential therapeutic target for papillary and follicular thyroid cancers.
authors.affiliation: Department of Surgery, University of Wisconsin School of Medicine and Public Health, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI 53792-7375, USA.
authors.forename: Xueming
authors.initials: X
authors.lastname: Xiao
authors.forename: Li
authors.initials: L
authors.lastname: Ning
authors.forename: Herbert
authors.initials: H
authors.lastname: Chen
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000473:pathology*; D015153:Blotting, Western; D002291:Carcinoma, Papillary / Q000201:enzymology / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D010957:Plasmids / Q000235:genetics; D051881:Receptor, Notch1 / Q000378:metabolism*; D013964:Thyroid Neoplasms / Q000201:enzymology / Q000473:pathology*; D014162:Transfection; D014635:Valproic Acid / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D051881:Receptor, Notch1; C528828:suberoyl bis-hydroxamic acid; D014635:Valproic Acid